Nasdaq 100 Stocks SEC Filings — April 24, 2026
Across 33 filings from NASDAQ-100 related entities, proxy statements dominate (18/33) signaling peak annual meeting season in May-June 2026, with positive executive comp and achievements in biotech/tech (e.g., Immunome exceeded targets 145-150%, Alphabet Gemini launch). Q1 2026 financials show semis rebounding (Intel rev +7.2% YoY to $13.6B, TI +18.6% to $4.8B) amid CHIPS incentives, but mixed elsewhere: telecom softness (Charter rev -1% YoY), coal disruptions (Alpha Met Q1 loss $11M), and sharp declines (ILAG rev -40.1% YoY). Capital returns strong (Comcast $11.7B buybacks/divs reducing shares 5%, TI $1.29B divs), with biotech funding wins (Altimmune $211M for Phase 3 MASH trial). Portfolio trends: Revenue growth avg +10% YoY in reporting cos (5/7), but losses prevalent (Intel $3.7B net loss, Blue Moon $38.8M); positive sentiment 12/33, mixed 10/33. Key implications: Watch proxy votes for equity plan approvals adding shares (Alphabet 200M Class C), semis for foundry ramps, biotechs for catalysts.